UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000005428 |
|---|---|
| Receipt number | R000005907 |
| Scientific Title | Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. |
| Date of disclosure of the study information | 2011/04/12 |
| Last modified on | 2020/04/19 17:21:01 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Acronym
Phase 1/2 study of Bendamustine and Rituximab for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Scientific Title
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Scientific Title:Acronym
Phase 1/2 study of Bendamustine and Rituximab for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Region
| Japan |
Condition
Condition
relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
In the phase I trial, primary objective is to estimate the maximum tolerated dose(MTD) and recommended dose(RD) of bendamustine and rituximab relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
In the phase II trial, primary objectives is to evaluate the efficacy and safety.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase I,II
Assessment
Primary outcomes
Phase 1
recommended dose
dose limiting toxicity
maximum tolerated dose
overall response rate
Phase 2
overall response rate
Key secondary outcomes
Phase 1
overall response rate
Phase 2
complete response rate
progression-free survival
safty
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Bendamustine+Rituximab
Phase 1
Rituximab Day1 375mg/m2/day
Bendamustine Day2, Day3
Level 1: 90mg/m2/day, every 21 days
Level 2: 90mg/m2/day, every 28 days
Level 3: 120mg/m2/day, every 21 days
Level 4: 120mg/m2/day, every 28 days
Rituximab is infused on Day1 and Bendamustine infusedon Day1, Day2 after 2 cycles.
Phase 2
Domestic recommended dose decided by phase 1 part
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1) Patients with pathologically confirmed indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma.
(2) Patients had received prior treatment of rituximab in combination with chemotherapy (without corticosteroid alone) or antibody treatments that rituximab alone or ibritumomab tiuxetan, and were considered no response or relapse after CR or PR.
(3) CD20 positive
(4) Patients have measurable lesion that measured >=1.5cm in a single dimension by CT.
(5) Patients aged 20-74 years.
(6) PS(ECOG) 0-2
(7) Patients meet all following standard
Absolute neutrophil count >= 1,500/mm3
Platelet count >= 100,000/mm3
AST and ALT < 2.5 times facility criteria.
Total bilirubin < 1.5 times facility criteria.
Creatinine < 1.5 times facility criteria.
Cardiac electro gram: no abnormality required treatment
SpO2: >= 90%
(8) Patients have a life expectancy > 3 months.
(9) Written informed consent.
Key exclusion criteria
(1) Patients are pregnant or lactating women.
Patients (<1 year after menopause without surgical infertility) can not or will not use birth control during the treatment
(2) Patients have active other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment for other cancer except curable intramural cancer by local treatment.
(3) Patients have mental disease or disorder with difficulty in participating in the clinical trial.
(4) HBs antigen positive
(5) HCV antibody positive
(6) HIV antibody positive
(7) Patients have much tumor cell in peripheral blood (>=25,000/mm3).
(8) Patients received allogeneic hematopoietic (hemopoietic) stem cell transplant.
(9) Patients have interstitial lung disease or fibroid lung.
(10) Patients have CNS invasion.
(11) Patients already received bendamustine treatment.
(12) Patients are inappropriate for rituximab treatment.
(13) Patients have severe allergic symptoms.
(14) Inadequate for clinical trial entry by the attending physicians.
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | Nozomi |
| Middle name | |
| Last name | Niitsu |
Organization
International Medical Center, Saitama Medical University
Division name
Department of Hematology
Zip code
350-1298
Address
1397 - 1, Yamane, Hidaka, Saitama, Japan
TEL
042-984-4111
ntakashi@saitama-med.ac.jp
Public contact
Name of contact person
| 1st name | Naoki |
| Middle name | |
| Last name | Takahashi |
Organization
International Medical Center, Saitama Medical University
Division name
Department of Hematology
Zip code
350-1298
Address
1397 - 1, Yamane, Hidaka, Saitama, Japan
TEL
042-984-4111
Homepage URL
ntakashi@saitama-med.ac.jp
Sponsor or person
Institute
Department of Hematology, International Medical Center, Saitama Medical University
Institute
Department
Personal name
Funding Source
Organization
Department of Hematology, International Medical Center, Saitama Medical University
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
IRB committee, International Medical Center, Saitama Medical University
Address
1397 - 1, Yamane, Hidaka, Saitama, Japan
Tel
042-984-4111
chikens@saitama-med.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 04 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2011 | Year | 02 | Month | 01 | Day |
Date of IRB
| 2011 | Year | 02 | Month | 01 | Day |
Anticipated trial start date
| 2011 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2020 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 04 | Month | 12 | Day |
Last modified on
| 2020 | Year | 04 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005907
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
